Marketing research of the market of drugs with the choleretic action

Abstract

Literary sources indicate that among hyperendemic diseases the problems of the biliary system take one of the leading places and are widely represented in all age groups. According to the Centre for Health Statistics of the Ministry of Public Health of Ukraine the number of patients with cholelithiasis grows, the increase in its prevalence for the last 10 years is 97.5%. The primary cause of the disease is the human life style, as well as conditions and the environment, genetic predisposition and activities of healthcare institutions. More often the treatment of cholelithiasis is associated with hospitalization and high financial cost. Annually there are more than 2.5 million operations on the bile ducts in the world. One of the alternative methods of treatment involves the use of drugs that are of natural and synthetic origin. Nowadays herbal medicines are gaining popularity. Prepared from herbs phytodrugs have a wide range of the therapeutic action with gradual, slow development of the therapeutic effect, high bioavailability, and patients can use them for a long time. Their action is not only aimed directly at treating disease, but also protecting and strengthening the organism as a whole. The aim of our work is to conduct the marketing research of the market of drugs with the choleretic action. It has been shown that the majority of the choleretic drugs range is formed by foreign producers, their share is 62% and domestic drugs are 38%. The countries importing drugs of the group under research have been studied. It has been proven that among the drugs with the choleretic action, tablets are the most common dosage form, their share is 55%. The results of the marketing analysis conducted allows to prove the expedience of creating combined medicinal products based on the plant raw material with a wide range of the therapeutic action that will have a high efficiency, quality and availability to the general public.

Histological research of hepatoprotective activity of tablets Lavaflam in rats with subchronic hepatitis

“…Experimental pharmacological studies were performed on the white rats weighing 180-220 g. The study was carried out in the Central Research Laboratory (CRL) of the National University of Pharmacy, Kharkiv, Ukraine (Certificate № 023/13 of 05.03.2013) according to the methodological recommendations of the State Expert Center of the Ministry of Health of Ukraine [5]. Rats that are included in the study were grown in the vivarium and before the experiment they were acclimated in the room for research during seven days.…”

“…1 tablet of Lavaflam contains 50 mg of Flamin and 20 mg of Lavender oil, medical form is tablets 0.6 grams № 50 ( Table 1) [3]. Lavaflam will be produced by the pharmaceutical company "Zdorovye" (Kharkіv, Ukraine).…”

Development of the composition and manufacturing technology of the new combined drug Lavaflam

“…According to statistics, in Ukraine, the number of such patients is constantly increasing. 5 Currently, combined drugs are the leading pharmacotherapeutic agents, including those for the treatment of diseases of the biliary system, which require complex treatment. The choice of drug combination allows to expand the range of action of the drug and the complex influence on the disease, enhance the activity of every ingredient, as well improve tolerability and reduce adverse effects.…”

“…They are characterized by high efficiency, low toxicity, and the possibility of long-term use without the risk of adverse effects. 5,8 Complex treatment of biliary disease is the reason for the creation of drugs of herbal origin, because herbal remedies usually possess many pharmacologic effects and have low levels of adverse effects. Nowadays, immortelle-containing drugs are widely used, which are well-known in the Ukraine and some countries of the former Soviet Union.…”